Faldaprevir is a protease inhibitor belonging to the HCV NS3/4A class, primarily developed for the treatment of chronic hepatitis C virus infection when used in combination with other antiviral therapies.… Read more
Faldaprevir is a protease inhibitor belonging to the HCV NS3/4A class, primarily developed for the treatment of chronic hepatitis C virus infection when used in combination with other antiviral therapies. This category comprises the parent drug alongside its various deuterated analogues, which serve as essential tools for analytical research and pharmaceutical development. Laboratories utilize these stable isotope-labelled compounds as high-precision internal standards in quantitative analysis, particularly for mass spectrometry-based assays. By providing a reliable reference for the active pharmaceutical ingredient, these labelled standards enable accurate identification and quantification of the drug in biological matrices. Researchers rely on these materials for robust impurity profiling, rigorous method validation, and consistent quality control, ensuring that analytical procedures meet regulatory standards throughout the drug development lifecycle.